Circulating Tumor Cells Screen for Breast Cancer (CTCSFBC)

Handan First Hospital

Status: Active, not recruiting

Conditions: Breast Neoplasm; Neoplastic Cells, Circulating

Treatments: Diagnostic Test: Peripheral blood sampling for circulating tumor cells

Study type: Observational

Funder types: Other

Identifiers

NCT05633680

handan1

20200187 (Other Grant/Funding Number)

Details and patient eligibility

About

A prospective study was used to collect patients considering breast cancer admitted to our general surgery department from 2019-6 to 2023-8, to identify the case group (breast cancer) and the control group (non-breast cancer), to compare the differences in CTC in peripheral blood between the two groups, and to draw conclusions after statistical analysis.

Full description

This project is a prospective study by collecting clinical data from breast cancer and non-breast cancer patients admitted to our general surgery department from 2020 to 2023, and drawing peripheral blood for CTC testing. The clinical data of 200 patients were initially collected and grouped, with the study group positioned as breast cancer patients (patients with pathologically determined breast cancer) and the control group as non-breast cancer patients (patients with benign breast tumors and healthy women), to investigate the expression of CTC in breast cancer and correlation with the degree of metastasis, as well as to further understand the relationship between CTC in peripheral blood and breast cancer clinicopathology. The circulating tumor cell enrichment was compared between the two groups, and the data were derived for statistical analysis to draw conclusions, as well as to identify shortcomings and make improvements to the existing problems.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Clinical diagnosis of breast cancer Must be able to cooperate with the examination

Exclusion criteria

patients were currently undergoing or had prior cancer treatment; patients had other conditions which investigators thought not suitable for the study.

Trial design

200 participants in 2 patient groups

Breast cancer group

Description:

Breast cancer is finally determined through breast puncture biopsy or excisional tissue biopsy and sent for pathological diagnosis

Treatment:

Diagnostic Test: Peripheral blood sampling for circulating tumor cells

Non-breast cancer group

Description:

By breast puncture biopsy or excisional tissue biopsy and sent to pathology for final determination of benign tumor. and healthy women

Treatment:

Diagnostic Test: Peripheral blood sampling for circulating tumor cells